Azonafide derived tumor and cancer targeting compounds

Details Azonafide derived tumor and cancer targeting compounds Azonafide derived tumor and cancer targeting compounds

2011-08-30

2011-08-30

Aulakh, Charanjit (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C546S076000, C544S361000, C514S002600, C514S253030

Reexamination Certificate

active

08008316

ABSTRACT:
An azonafide-based compound of Formula I, a composition comprising the compound, and a method of using the compound to deliver a cytotoxic azonafide derivative to a cell, as well as related compounds and methods for the use thereof to pre-pare an azonafide-based compound of Formula I.

REFERENCES:
patent: 5635506 (1997-06-01), Alberts et al.
patent: 5703089 (1997-12-01), Braña et al.
patent: WO 92/00281 (1992-01-01), None
patent: WO 03/072754 (2003-09-01), None
patent: WO 2006/060533 (2006-06-01), None
Czerwinski et al., “Cytotoxic agents directed to peptide hormone receptors: Defining the requirements for a successful drug,”PNAS, 95, 11520-11525 (1998).
Dorr et al., “Preclinical antitumor activity of the azonafide series of anthracene-based DNA intercalators,”Anticancer Drugs, 12 (3), 213-220 (2001).
Dyba et al., “Small Molecule Toxins Targeting Tumor Receptors,”Curr. Pharm. Des., 10, 2311-2334 (2004).
Jaracz et al, “Recent advances in tumor-targeting anticancer drug conjugates,”Bioorg. Med. Chem., 13, 5043-54 (2005).
Langer, “New Methods of Drug Delivery,”Science, 249, 1527-1533 (1990).
Sami et al., “2-substituted 1,2-Dihydro-3H-dibenz[de,h]isoquinoline-1,3-diones. A new class of antitumor agent,”J. Med. Chem., 36, 765-770 (1993).
Sami et al., “Amino-Substituted 2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H-dibenz[de,h]isoquinoline-1,3-diones. Synthesis, antitumor activity, and quantitative structure—activity relationship,”J. Med. Chem., 38, 983-993 (1995).
Sami et al., “6- and 7-substituted 2-[2'-(Dimethylamino)ethyl]-1,2-dihydro-3H-dibenz[de,h] isoquinoline-1,3-diones: synthesis, nucleophilic displacements, antitumor activity, and quantitative structure-activity relationships,”J. Med. Chem., 39, 1609-1618 (1996).
Sami et al., “2-[2'-(Dimethylamino)ethyl]-1,2-dihydro- 3H-dibenz[de,h]isoquinoline-1,3-diones with substituents at positions 4, 8, 9, 10, and 11. Synthesis, antitumor activity, and quantitative structure-activity relationships,”J. Med. Chem., 39, 4978-87 (1996).
Sami et al., “Analogues of amonafide and azonafide with novel ring systems,”J. Med. Chem., 43, 3067-3073 (2000).

Affiliated with

Also associated with

Rating

Azonafide derived tumor and cancer targeting compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Azonafide derived tumor and cancer targeting compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Azonafide derived tumor and cancer targeting compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2648863